Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04306900 · ClinicalTrials.gov registry record · Phase 1
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
A Phase 1 study, sponsored by Trishula Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 185
- Enrollment target
NCT04306900: Completed Phase 1 study, sponsored by Trishula Therapeutics.
NCT04306900 is a Phase 1 study that has completed, run by Trishula Therapeutics. The registered enrollment target is 185 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (208% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04306900, a Phase 1 study, has completed, sponsored by Trishula Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 185 participants
- Enrollment target
Study Summary
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Primary Outcome
A DLT was defined as the occurrence of any of the following toxicities within the DLT Evaluation Period if judged by the Investigator and Sponsor to be possibly, probably, or definitely related to TTX-030 or budigalimab.
Interventions
- COMBINATION_PRODUCT TTX-030, budigalimab, nab-paclitaxel and gemcitabine
- COMBINATION_PRODUCT TTX-030, budigalimab and mFOLFOX6
- COMBINATION_PRODUCT TTX-030, budigalimab and docetaxel
- COMBINATION_PRODUCT TTX-030 and mFOLFOX6
- COMBINATION_PRODUCT TTX-030 and budigalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2020-03-30 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 1 |
What the finished NCT04306900 record still lists
NCT04306900 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (208% higher).
The record links to 0 conditions, and to 5 interventions - of which TTX-030, budigalimab, nab-paclitaxel and gemcitabine is the first listed.
NCT04306900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04306900 about?
NCT04306900 is a clinical study titled "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers". This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor i...
What is the current status of trial NCT04306900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 185 participants. The study started on 2020-03-30. Estimated completion is 2024-03-27.
What interventions are being tested in trial NCT04306900?
The interventions under investigation include: TTX-030, budigalimab, nab-paclitaxel and gemcitabine (COMBINATION_PRODUCT), TTX-030, budigalimab and mFOLFOX6 (COMBINATION_PRODUCT), TTX-030, budigalimab and docetaxel (COMBINATION_PRODUCT), TTX-030 and mFOLFOX6 (COMBINATION_PRODUCT), TTX-030 and budigalimab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04306900?
This trial is sponsored by Trishula Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04306900's enrollment target sits among peer trials
185 294th of 2000 higher than 1,707 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI